SCHEMBL4772868

SCHEMBL4772868

Cc1ccc(-c2cc(CCl)ccn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 3/20 0.43
KDM1A O60341 3/20 0.42
HDAC1 Q13547 3/20 0.42
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HDAC6 Q9UBN7 1/20 0.40
TGFBR1 P36897 1/20 0.40
SREBF2 Q12772 2/20 0.39
SREBF1 P36956 1/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2A6 P11509 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128508 0.84 MAP4K4 (0.46) LOXL2MEN1KMT2ATGFBR1SREBF2
SCHEMBL4117407 0.82 LOXL2 (0.43) LOXL2MEN1KMT2ATGFBR1SREBF2
SCHEMBL4764104 0.82 RECQL (0.47) LOXL2KDM1AHDAC1CCR1CCR5
SCHEMBL4775515 0.82 ASIC3 (0.50) LOXL2ALDH1A1KDM4E
SCHEMBL3958545 0.81 CCR1 (0.65) LOXL2CCR1CCR5CCR8MEN1
SCHEMBL29693626 0.81 CCR1 (0.65) LOXL2CCR1CCR5CCR8MEN1
SCHEMBL4116786 0.81 ASIC3 (0.53) LOXL2MEN1KMT2ATGFBR1ALDH1A1
SCHEMBL4769299 0.81 NPC1 (0.47) KDM1AHDAC1CCR1CCR5CCR8
SCHEMBL27602586 0.81 LOXL2 (0.56) LOXL2CYP2A6
SCHEMBL29558394 0.80 CCR1 (0.42) LOXL2CCR1CCR5CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 LOXL2 4426/4885KDM1A 2917/4885HDAC1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.